Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $13.7 million.

  • Xeris Biopharma Holdings' Other Operating Expenses fell 1592.86% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.9 million, marking a year-over-year increase of 1349.44%. This contributed to the annual value of $47.7 million for FY2024, which is 2073.29% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Other Operating Expenses is $13.7 million, which was down 1592.86% from $14.6 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Operating Expenses peaked at $16.3 million during Q3 2024, and registered a low of $1.8 million during Q1 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Other Operating Expenses value was $9.0 million (recorded in 2022), while the average stood at $9.2 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Other Operating Expenses tumbled by 4169.17% in 2021 and then surged by 39200.44% in 2022.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Other Operating Expenses stood at $5.4 million in 2021, then soared by 65.51% to $9.0 million in 2022, then rose by 14.21% to $10.3 million in 2023, then rose by 18.56% to $12.2 million in 2024, then rose by 12.45% to $13.7 million in 2025.
  • Its Other Operating Expenses stands at $13.7 million for Q3 2025, versus $14.6 million for Q2 2025 and $11.4 million for Q1 2025.